JeromeRitzMD

Hematology • Boston, MA

Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Ritz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ritz's full profile

Already have an account?

Office
450 Brookline Ave
M530, Dana-Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-3465

Fax+1 617-632-5167

Summary

Dr. Jerome Ritz is a hematologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital and Dana-Farber Cancer Institute. He is Professor of Medicine at Harvard Medical School. He received his medical degree from Chicago Medical School at Rosalind Franklin University and has been in practice 45 years. He specializes in hematologic oncology and is experienced in hematologic oncology, hematopoietic stem cell transplantation and cellular therapies. He is currently Executive Director of the Connell and O'Reilly Families Cell Manipulation Core Facility.

Education & Training

University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1972 - 1975
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1972
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology

Certifications & Licensure

MA State Medical License 1976 - 2025
CO State Medical License 1975 - 1980
WI State Medical License 1973 - 1979
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Elected Member Association of American Physicians, 2021
Elected Member The American Society for Clinical Investigation, 1990
Super Doctor SuperDoctors.com

Publications & Presentations

PubMed

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma.
Katie Maurer, Isabella N Grabski, Roch Houot, Satyen H Gohil, Shogo Miura
Blood. 2024-12-12
A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treat...
Eric Jacobsen, Ashley Plant, Robert Redd, Philippe Armand, Mikaela McDonough
Leukemia & Lymphoma. 2024-12-01
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations.
Livius Penter, Nicoletta Cieri, Katie Maurer, Marwan Kwok, Haoxiang Lyu
Blood Cancer Discovery. 2024-11-01

Journal Articles

Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease
Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood
Immunophenotyping of Pediatric Brain Tumors: Correlating Immune Infiltrate with Histology, Mutational Load, and Survival and Assessing Clonal T Cell Response
Isaac H Solomon, Mark W Kieran, Gabriel K Griffin, Pratiti Bandopadhayay, Jerome Ritz, Ashley S Plant, Keith L Ligon, Glenn Dranoff, Journal of Neuro-Oncology

Abstracts/Posters

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Gut Bacteria Engineered to Act as Tumor GPS for ImmunotherapiesOctober 4th, 2024
New Research Offers Hope for Safer and More Effective Blood Stem Cell TransplantsSeptember 4th, 2024
National Cancer Center Is Pleased to Name David Knorr, M.D., Ph.D., to Scientific Advisory BoardOctober 25th, 2022
Join now to see all